• Video
  • Shop
  • Culture
  • Family
  • Wellness
  • Food
  • Living
  • Style
  • Travel
  • News
  • Book Club
  • Newsletter
  • Privacy Policy
  • Your US State Privacy Rights
  • Children's Online Privacy Policy
  • Interest-Based Ads
  • Terms of Use
  • Do Not Sell My Info
  • Contact Us
  • © 2026 ABC News
  • News

FDA approves first generic EpiPen

0:48
FDA approves first generic EpiPen
Mark Zaleski/AP, FILE
ByJulia Jacobo
August 16, 2018, 6:14 PM

The U.S. Food and Drug Administration has approved the first generic version of the EpiPen and EpiPen Jr auto injector for the emergency treatment of allergic reactions.

The approval is part of the FDA's "longstanding commitment" to providing access to low-cost generic alternatives, FDA Commissioner Scott Gottlieb said in a statement.

"This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages," the commissioner said.

It is unclear how much the generic product -- manufactured by Teva Pharmaceuticals -- will cost. In August 2016, Mylan Pharmaceuticals was criticized for raising the price of a two-pack of EpiPens to $600.

The price of two EpiPens was about $100 in 2009. The brand name version is by far the most popular epinephrine auto-injector on the market.

Related Articles

(MORE: What to know about the anticipated EpiPen shortage)

The generic version of "the most widely-prescribed epinephrine auto-injector in the U.S." has been approved for adults and children who weigh more than 33 pounds, Gottlieb said. It can be used to treat life-threatening allergic reactions from insect bites or stings, food medications, latex and other causes, according to the FDA.

The generic auto-injector is also intended for immediate administration of epinephrine, which works by reducing swelling in the airway and increasing blood flow in the veins.

Related Articles

(MORE: EpiPen maker Mylan settles with DOJ for $465M over Medicaid allegations)

"Combination products," such as epinephrine auto-injectors that include both a drug and a device, are "more challenging than typical drug products" to develop generic versions, according to the FDA.

Complex products are "hard to copy" and often take a long time, Gottlieb said, adding that the FDA is working on more efficient ways to develop generic products.

"We’re advancing new guidance for sponsors to make the development of generic versions of complex products more efficient, and we’re prioritizing review of many complex generic drug applications," he said.

Related Articles

(MORE: Generic EpiPen could still be costly for families)

An "authorized generic" is made using the brand name's existing new drug application and uses the same formulation, process and manufacturing facilities used by the brand name manufacturer, according to the FDA. The label and packaging used by the brand name are also changed.

Up Next in News—

Residents fight to keep AI data center campus away from Nashville Zoo

June 12, 2026

Mom says her 10-year-old daughter saved family from house fire

June 12, 2026

Man sues law enforcement alleging AI facial recognition technology led to wrongful arrest

June 12, 2026

What current, future retirees should know about potential Social Security shortfall

June 11, 2026

Shop GMA Favorites

ABC will receive a commission for purchases made through these links.

Sponsored Content by Taboola

The latest lifestyle and entertainment news and inspiration for how to live your best life - all from Good Morning America.
  • Contests
  • Terms of Use
  • Privacy Policy
  • Do Not Sell My Info
  • Children’s Online Privacy Policy
  • Advertise with us
  • Your US State Privacy Rights
  • Interest-Based Ads
  • About Nielsen Measurement
  • Press
  • Feedback
  • Shop FAQs
  • ABC News
  • ABC
  • All Videos
  • All Topics
  • Sitemap

© 2026 ABC News
  • Privacy Policy— 
  • Your US State Privacy Rights— 
  • Children's Online Privacy Policy— 
  • Interest-Based Ads— 
  • Terms of Use— 
  • Do Not Sell My Info— 
  • Contact Us— 

© 2026 ABC News